Pro Medicus (ASX:PME) share price in focus on 2023 AGM

The Pro Medicus Ltd (ASX:PME) share price is currently higher after the company held its AGM and gave some promising updates.

You’re reading a free article on Rask. Join 4,000+ Australians who get our expert advice, tools, exclusive research and investment recommendations. Get your 30-day trial for $1! Learn more

The Pro Medicus Ltd (ASX: PME) share price is currently higher after the company held its AGM.

Pro Medicus provides a full range of medical imaging software and services to hospitals, imaging centres and healthcare groups around the world.

Acquisitions?

The company’s cash and ‘other financial assets’ continues to grow, which enable the business to invest in developing its product suite, including AI, paying its dividends and take advantage of acquisition opportunities.

Pro Medicus said that while no acquisitions to date have met its criteria, the current circumstances surrounding the technology sector has meant the board is “starting to see valuations coming down such that an increasing number of opportunities may meet” its criteria in the future.

Dividend policy

In FY23 it grew its annual dividend by 36% to 30 cents per share, representing a dividend payout ratio of approximately 50%. The dividend was funded from the company’s internally generated cash flow.

Pro Medicus’ board expects that future dividends will continue to be fully franked.

The board will determine the appropriate level of dividends by looking at the “profitability of the business, its need for ongoing investment and the necessity to retain sufficient funds to pursue other growth opportunities.”

Growth plans

Pro Medicus said it has a plan for strong growth between FY24 to FY26.

The board and management have set “aggressive” growth targets in keeping with the company’s current and potential opportunities. It said it’s in the process of progressively implementing its plans to achieve the next growth phase.

Final thoughts on the Pro Medicus share price

Pro Medicus is probably the best business on the ASX. It has enormous profit margins, it’s growing and compounding at a fast pace, the dividend growth and balance sheet are excellent, and management seem extremely capable. And it keeps winning new contracts.

However, it’s priced for its excellence with an incredibly high price/earnings ratio (p/e ratio). Despite all of the interest rate hikes, the p/e ratio has increased over time.

It seems too expensive to buy shares today, but I’ve said that quite a few times over the years and now look where it is! If I were a shareholder, I’d be very pleased by what I’m seeing, including with this update.

CSL, Xero, ANZ... the ASX is beaten up

Right now, only brave investors are buying. Is ASX Reporting Season your KEY opportunity to act? Buy, or sell.

This coming Monday night, our two most experienced professional investors, Owen Rask and Leigh Gant, are hosting an exclusive and rare webinar on the what to watch this ASX reporting season. LIVE and free

With over 35 years of combined investing experience, join our Chief Investment Officer and Head of Content for our free Q&A.

We’ll be diving into results from CSL, Pro Medicus (ASX: PME), ANZ Bank and more. It’s absolutely free to join us. Take advantage of this volatility with our free playbook. Simply click here to view the topics.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.

A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

How can Rask help you?

About Rask

Learn more about us, our your community and our mission.

Rask investing philosophy

Nearly 15 years later.
It's still a work in progress.

Online investment community

You won't find our investment community on Facebook or Reddit because it's secure, free and available now.

Join 250,000+ podcast listeners

250,000 investors tune into the Rask podcasts every month. Find out why.

Find a financial planner

Australia's financial experts. At your doorstep.

Free finance courses

35,000 students have enrolled in free Rask courses. We're on a mission to 100,000.

Subscribe to Rask's free investor newsletter

53,000 Australian investors subscribe to our Sunday newsletter... and love it! It's free.

$50 million invested

We manage almost $50 million on behalf of Aussies. Discover how you can invest with us.

Better investing starts here.

Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best  insights.

Subscribe to Rask's free investor newsletter

Kick off your week with our pick of podcasts, courses and investing resources to keep your finger on the Rask pulse!

Here you go: A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.